Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985;19(Suppl 2):171S–175S. doi: 10.1111/j.1365-2125.1985.tb02758.x

Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms in healthy volunteers

P N Bennett, J Bennett, I Bradbrook, J Francis, V A John, H Rogers, P Turner, S J Warrington
PMCID: PMC1463746  PMID: 4005119

Abstract

1 Oxprenolol was administered in single doses by mouth to healthy volunteers either in a polymer-matrix slow-release formulation (Slow Trasicor®) or in osmotic drug-delivery systems (oxprenolol Oros). Plasma oxprenolol concentrations and heart rates after exercise were measured.

2 Plasma concentrations of the drug were maximal at 3 h but negligible at 24 h after administration of Slow Trasicor. Following ingestion of the Oros systems measurable concentrations were maintained throughout 24 h.

3 Significant reduction of exercise-induced tachycardia persisted for 24 h after administration of oxprenolol Oros. With Slow Trasicor heart rate responses had returned to baseline values by this time.

4 The osmotic drug-delivery systems appear to sustain significant β-adrenoceptor blockade for 24 h after a single oral dose.

Keywords: oxprenolol, Oros, dosage, form, plasma, concentrations, β-adrenoceptor, blockade

Full text

PDF
171S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brunner L., Imhof P., Jack D. Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man. Eur J Clin Pharmacol. 1975;8(1):3–9. doi: 10.1007/BF00616408. [DOI] [PubMed] [Google Scholar]
  2. Degen P. H., Riess W. Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography. J Chromatogr. 1976 Jun 9;121(1):72–75. doi: 10.1016/s0021-9673(00)82299-2. [DOI] [PubMed] [Google Scholar]
  3. Mason W. D., Winer N. Pharmacokinetics of oxprenolol in normal subjects. Clin Pharmacol Ther. 1976 Oct;20(4):401–412. doi: 10.1002/cpt1976204401. [DOI] [PubMed] [Google Scholar]
  4. Theeuwes F., Swanson D. R., Guittard G., Ayer A., Khanna S. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. Br J Clin Pharmacol. 1985;19 (Suppl 2):69S–76S. doi: 10.1111/j.1365-2125.1985.tb02745.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES